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Abstract
Background: Chronic lung disease (CLD) in the preterm newborn is associated with inflammation
and fibrosis. Platelet-derived growth factor-BB (PDGF-BB), a potent chemotactic growth factor,
may mediate the fibrotic component of CLD. The objectives of this study were to determine if
tracheal aspirate (TA) concentrations of PDGF-BB increase the first 2 weeks of life in premature
neonates undergoing mechanical ventilation for respiratory distress syndrome (RDS), its
relationship to the development of CLD, pulmonary hemorrhage (PH) and its relationship to airway
colonization with Ureaplasma urealyticum (Uu).
Methods: Infants with a birth weight less than 1500 grams who required mechanical ventilation
for RDS were enrolled into this study with parental consent. Tracheal aspirates were collected
daily during clinically indicated suctioning. Uu cultures were performed on TA collected in the first
week of life. TA supernatants were assayed for PDGF-BB and secretory component of IgA
concentrations using ELISA techniques.
Results: Fifty premature neonates were enrolled into the study. Twenty-eight infants were oxygen
dependent at 28 days of life and 16 infants were oxygen dependent at 36 weeks postconceptual
age. PDGF-BB concentrations peaked between 4 and 6 days of life. Maximum PDGF-BB
concentrations were significantly higher in infants who developed CLD or died from respiratory
failure. PH was associated with increased risk of CLD and was associated with higher PDGF-BB
concentrations. There was no correlation between maximum PDGF-BB concentrations and Uu
isolation from the airway.
Conclusions: PDGF-BB concentrations increase in TAs of infants who undergo mechanical
ventilation for RDS during the first 2 weeks of life and maximal concentrations are greater in those
infants who subsequently develop CLD. Elevation in lung PDGF-BB may play a role in the
development of CLD.
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Chronic lung disease (CLD) in the preterm newborn,
commonly referred to as bronchopulmonary dysplasia
(BPD), occurs as a result of acute lung injury (ALI) due to
several factors including mechanical ventilation and oxy-
gen therapy during the first days of life [1]. It affects as
many as 43% of infants born weighing less than 1000
grams and 23% of infants weighing less than 1500 grams.
The development of CLD is associated with poor neurode-
velopmental outcome and chronic pulmonary morbidity
[2].
Acute lung injury in the premature newborn is associated
with inflammation and may result in lung fibrosis.
Inflammation, characterized by an influx of neutrophils
and macrophages with the release of pro-inflammatory
and chemotactic cytokines, is followed by variable degrees
of intraalveolar and interstitial fibrosis, airway maldevel-
opment and failure of septation, all of which ultimately
alter the development of the immature lung [3-5]. Previ-
ous research into respiratory distress syndrome (RDS) in
the newborn has identified several inflammatory media-
tors which may play a role in the development of CLD
[3,6-11]. The potential role of growth factors in the devel-
opment of CLD has been studied to a lesser degree. One
of the many growth factors that may play a role in the
development of CLD in the newborn is platelet derived
growth factor (PDGF). PDGF a family of homo and het-
erodimers of disulfide-bonded A and B polypeptide
chains resulting in 3 isoforms AA, AB, and BB, is synthe-
sized by a variety of cells including macrophages,
endothelial cells and fibroblasts [12]. PDGF-BB is a potent
chemotactic and a "competence" growth factor for fibrob-
lasts and smooth muscle cells, and has been implicated in
the pathogenesis of fibrotic lung conditions [12-21].
Fibrosis is also a component in CLD in some newborns.
However, the role PDGF-BB may play in CLD in the pre-
term newborn remains undefined.
This study was conducted to determine if PDGF-BB con-
centrations increase during the first 2 weeks of life in
mechanically ventilated premature neonates with RDS
and to evaluate the relationship between PDGF-BB and
the subsequent development of CLD. In addition, the
impact of airway colonization with Ureaplasma urealyti-
cum (Uu) and pulmonary hemorrhage (PH) on tracheal
aspirate concentrations of PDGF-BB was assessed.
Methods
The study population consisted of very low birth weight
infants admitted to the neonatal intensive care unit at the
Louisiana State University Health Sciences Center in
Shreveport. Many of these subjects have been reported in
our earlier studies of inflammatory mediators and the
development of BPD [22,23]. Eligibility criteria included
a birth weight of less than 1500 grams, RDS requiring
mechanical ventilation during the first week of life and
parental consent. The study was approved by the Institu-
tional Review Board for Human Research at Louisiana
State University Health Sciences Center.
Tracheal aspirates were collected daily during clinically
indicated suctioning procedures using a standardized
technique. Sterile normal saline (0.5 ml) was instilled
into the endotracheal tube and 3–4 manual breaths were
provided by a self inflating resuscitation bag. Airway
secretions were aspirated into sterile traps and any mate-
rial remaining in the catheter was washed into the trap
with an additional 0.5 cc saline. Tracheal aspirates were
centrifuged 14,000 g for 10 minutes to remove cellular
material and the supernatant frozen at -70°C until
cytokine assays performed. Uu cultures were performed
on TA collected in the first week of life. TA supernatants
were assayed for PDGF-BB concentrations using enzyme-
linked immunoadsorbent assay (ELISA) developed in our
laboratory using commercially available reagents. TA
PDGF-BB concentrations were normalized to secretory
component to account for variation in collection
volumes.
Clinical data collected included the following: need for
surfactant therapy, duration of mechanical ventilation,
use of postnatal corticosteroids, and the incidence of pat-
ent ductus arteriosus (PDA) and pulmonary hemorrhage
(PH).
Ureaplasma Culture
TA samples were cultured for the presence of Uu using the
following selective growth media: SP4 with urea (Remel,
Lexana, KS), Mycotrim GU® system (Irvine Scientific,
Santa Anna, CA), as well as urea and arginine-enriched
pleuropneumonia-like organism broths [24]. Fifty micro-
liters of TA were cultured in 2 ml of the appropriate
broths. An additional 50 µL of TA was placed into a
Mycotrim flask and subsequently incubated at 37°C in
5% CO2. The media was inspected twice a day for the first
2 days and then inspected daily for 5 days to observe any
color change in the media indicative of a positive culture.
Ureaplasma identification was confirmed by microscopic
examination of the distinct colony characteristics of urea-
plasmas on the solid media in the Mycotrim flask.
ELISA
Recombinant PDGF rβ/Fc Chimera and biotinylated
monoclonal anti-human PDGF-BB were purchased from
R&D Systems (Minneapolis, MN). Recombinant human
PDGF was purchased from Pepro Tech (Rocky Hill, NJ).
Streptavidin-horseradish peroxidase conjugate (Strept-
HRP) were purchased from Pharmingen (San Diego, CA).
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secretory component antibodies, and bovine serum albu-
min were purchased from Sigma Chemical Co (St. Louis,
MO). Human secretory immunoglobulin A (IgA) was pur-
chased from ICN Biomedicals (Costa Mesa, CA). ELISA
plates were obtained from Costar (Cambridge, MA). 2,2'-
azino-di [3-ethyl-benzthiazoline] (TMB) peroxidase sub-
strate kits were purchased from Bio-Rad (Hercules, CA).
Tracheal aspirate concentrations were measured by a
modification of the enzyme linked immunosorbent assay
which employs a PDGF receptor β Fc chimera as the first
layer of the assay. ELISA plates were coated with 100 µL of
recombinant PDGF rβ/Fc Chimera (0.4 µg/ml) in phos-
pate-buffered saline (pH 7.4) and incubated overnight at
4°C. After coating, the ELISA plates were washed once (4
minutes) with 200 µL of phosphate-buffered saline con-
taining 0.05% Tween 20 (wash buffer). All subsequent
washes were performed similarly. The plates were then
blocked using 200 µL of phosphate-buffered saline/
Tween 20 containing 3% (w/v) bovine serum albumin
(blocking buffer) for 1–2 hours at room temperature.
After blocking, the plates were washed three times before
use. TA samples and recombinant PDGF-BB standards
were appropriately diluted in blocking buffer. One hun-
dred microliters of diluted TA sample (diluted 1:2 in
blocking buffer) or standards (3.9 – 1000 pg/ml) was
incubated overnight at 4°C. Plates were washed four
times and incubated with 100 µL of biotinylated mono-
clonal anti-human PDGF-BB (100 ng/ml) for 2 hours at
room temperature. Plates were washed four times and
then incubated with Strept-HRP for 30 minutes at room
temperature. Plates were washed four times and then
developed with TMB substrate. The reaction was stopped
with H2SO4 (1:40) and the plated read at 450 nm using an
ELISA autoreader (Cayman Chemical, Ann Arbor, MI).
Measurement of secretory component was performed
using an assay previously described [23]. According to
manufacturer's specification, the PDGF-BB assay has
shows less than 2% cross-reactivity with PDGF-AB and
less than 0.6% cross-reactivity with PDGF-AA. Sensitivity
of the PDGF-BB assay was 16 pg/ml and secretory compo-
nent 3 ng/ml.
Data analysis
To adjust for variation in collection of TAs, PDGF-BB con-
centrations were normalized to secretory component [25].
Samples with secretory component concentrations less
than 20 µg/ml were considered too dilute and were
excluded from analysis. All statistical analysis was per-
formed using GB-Stat for Windows version 7.0 (Dynamic
Microsystems, Silver Spring, MD). The Fishers exact test (2
tailed) was used to assess the statistical differences in cat-
egorical variables. The Student t-test was used to assess
normally distributed variables. The Wilcox Rank Sum test
was used for analysis of factors that were not normally dis-
tributed. The differences in tracheal aspirate PDGF con-
centrations were assessed using ANOVA. Post hoc analysis
of daily TA cytokine concentrations was performed using
the Newman-Keuls test. A probability value of less than
0.05 was considered statistically significant. The data are
presented as mean ± standard error of the mean (SEM).
The definition of CLD in the preterm neonate or BPD has
undergone revision since it was first coined and currently
several definitions are commonly used [26-28]. Both oxy-
gen dependency at 28 days with a compatible chest X-ray
and oxygen dependency at 36 weeks PCA predict long
term adverse outcomes [28]. Because of this, TA PDGF-BB
concentrations were correlated to both of these outcomes.
Table 1: Clinical Characteristics of Study Subjects
Off Oxygen at 28 days (n = 16) Oxygen at 28 days (n = 28) Died (n = 6) P value1 P value2
Birth Weight 1112 ± 47 799 ± 35 751 ± 101 <0.001 0.002
Gestation 27.9 ± 0.4 26.1 ± 0.3 24.5 ± 0.6 0.001 <0.001
Surfactant 16 (100) 27 (96) 6 (100) 1.00 1.00
Prenatal Steroids 14 (88) 19 (68) 3 (50) 0.278 0.100
Uu isolated 4 (25) 14 (50) 2 (33) 0.105 1.000
PDA 7 (44) 14 (50) 3 (50) 0.835 1.000
Indomethacin3 13 (81) 28 (100) 6 (100) 0.042 0.532
Duration IMV (days) 8 ± 1 40 ± 6 15 ± 1 <0.001 0.013
Duration O2 (days) 19 ± 3 79 ± 9 15 ± 1 <0.001 0.479
Postnatal Steroids 5 (31) 25 (89) 6 (100) <0.001 0.012
Age Steroids Started 11.6 ± 2.8 11.5 ± 1.5 6.8 ± 3.0 0.973 0.129
PH 0(0) 7 (25) 3 (50) 0.037 0.013
IVH 2 (13) 12 (43) 3 (50) 0.039 0.100
Data are presented as Mean ± SEM or number with percentage in parenthesis 1 O2 at 28 days vs not on O2 at 28 days 2deaths vs not on O2 at 28 
days 3Indomethacin was used prophylactically in most cases Uu Ureaplasma urealyticum PDA Patent ductus arteriosus PH Pulmonary hemorrhage 
IVH Intraventricular hemorrhagePage 3 of 11
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Fifty premature neonates were enrolled into the study. Of
the fifty infants, 28 (56%) infants were oxygen dependent
at 28 days of life and 16 (32%) infants required oxygen
therapy at 36 weeks postconceptual age (PCA). Patient
characteristics can be found in Tables 1 and 2. Those
infants who were oxygen dependent at 28 days or died
from respiratory failure (n = 6) were born at an earlier ges-
tational age, had lower birth weight, more likely to suf-
fered a PH and more likely received postnatal
corticosteroids. However, the isolation of Uu from the air-
ways or the presence of a PDA was similar between the
two groups. Infants who remained oxygen dependent at
36 weeks PCA were similarly more immature, tended to
be of lower birth weight, and more likely received postna-
tal corticosteroids than those weaned from oxygen by this
time.
From the 50 infants studied, 436 tracheal aspirate samples
were analyzed with PDGF-BB concentrations detected in
230 (53%) samples. The frequency of detectable PDGF-
BB concentrations was significantly lower in infants who
did not develop BPD (p = 0.006): 37/100 (37%) in
infants who recovered from RDS and were off oxygen at
28 days, 162/279 (58%) in infants who were O2 depend-
ent at 28 days of life, 28/52 (54%) in infants who died,
90/159 (56%) in infants who were O2 dependent at 36
weeks PCA. Figure 1 illustrates the changes in TA concen-
trations of PDGF-BB during the first 14 days of life in
infants with RDS requiring mechanical ventilation. Tra-
cheal aspirate concentrations of PDGF-BB increased sig-
nificantly during the course of RDS. PDGF-BB
significantly increased until days 4–6 (mean peak at day
5) and then declined to baseline levels between 12 and 14
days of life (p < 0.001, ANOVA repeated measures). We
found no relationship between PDGF-BB concentrations
and gestational age (data not shown).
Tracheal aspirate concentrations of PDGF-BB and the 
development of chronic lung disease
Tracheal aspirate concentrations of PDGF-BB correlated
with the development of chronic lung disease. Figure 2
shows the TA concentrations of PDGF-BB in infants who
were or were not oxygen dependent at 28 postnatal days.
Concentrations of PDGF-BB were greater in those infants
who were oxygen dependent at 28 days of life. Theses
same trends persisted in the more severely affected infants
who remained oxygen dependent at 36 weeks PCA (Figure
3).
Because infants varied with respect to the timing of their
inflammatory processes, we examined the relationship of
maximal TA PDGF-BB concentrations and the
development of chronic lung disease. In infants who sub-
sequently were oxygen dependent at 36 weeks, maximum
PDGF-BB concentrations were significantly higher com-
pared to those who weaned from oxygen by this time (Fig-
ure 4A). Similarly maximum PDGF-BB concentrations
were greater in those infants with the combined outcome
of oxygen dependency at 36 weeks PCA or death from res-
piratory failure compared to survivors who were weaned
from oxygen by 36 weeks PCA (Figure 4B). Maximum
PDGF-BB concentrations were higher in infants who died
compared to those who survived and weaned from oxy-
gen (3416 ± 879 pg/µg Sec vs 825 ± 251 pg/µg Sec; p =
0.033) but not different between those who died and all
survivors (3416 ± 879 pg/µg Sec vs. 2374 ± 762 pg/µg Sec;
p = 0.622) The peak PDGF-BB response occurred later in
infants who required oxygen at 28 days compared to those
who were weaned from oxygen by 28 days (2.9 ± 0.5 days
Table 2: Characteristics of surviving infants with or without Oxygen Dependancy at 36 Weeks PCA
Off Oxygen at 36 weeks (n = 28) Oxygen at 36 weeks PCA (n = 16) P Value
Birth Weight 1011 ± 43 741 ± 38 <0.001
Gestation 27.1 ± 0.3 26.1 ± 0.4 0.057
Surfactant 27 (96) 16 (100) 1.00
Prenatal Steroids 22 (78) 11 (69) 0.492
Uu isolated 13 (46) 5 (31) 0.324
PDA 13 (46) 8 (50) 0.907
Indomethacin1 25 (89) 16 (100) 0.290
Duration IMV (days) 15 ± 2 53 ± 8 <0.001
Duration O2 (days) 30 ± 4 106 ± 13 <0.001
Postnatal Steroids 14 (50) 16 (100) <0.001
Age Steroids Stated 10.0 ± 1.2 12.8 ± 2.1 0.282
PH 3 (11) 4 (25) 0.236
IVH 6 (21) 8 (50) 0.503
Data are presented as Mean ± SEM or number with percentage in parenthesis 1Indomethacin was used prophylactically in most cases Uu 
Ureaplasma urealyticum PH Pulmonary hemorrhage PDA Patent ductus arteriosus IVH Intraventricular hemorrhagePage 4 of 11
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response was similar between infants who required oxy-
gen at 36 weeks PCA and those off oxygen at 36 weeks (5.3
± 0.8 days vs. 4.5 ± 0.6 days; p = 0.436) and between
infants who died and those weaned from oxygen before
28 days (5.1 ± 0.7 days vs. 4.5 ± 0.6 days; p = 0.495)
Postnatal factors and TA PDGF-BB concentrations
The role of airway colonization with Uu and PH on TA
PDGF concentrations and the subsequent development of
CLD were also examined. Infants with a clinically signifi-
cant PH had a statistically significant increase in their
maximum PDGF-BB concentrations (Figure 5A). Infants
Tracheal aspirate concentrations of PDGF-BB normalized to secretory component (sc) in mechanically ventilated infants with RDS during the first 14 days f lifeFigur  1
Tracheal aspirate concentrations of PDGF-BB normalized to secretory component (sc) in mechanically ventilated infants with 
RDS during the first 14 days of life. Concentrations of PDGF-BB increased significantly during the course of RDS. Data repre-
sent mean ± SEM. Numbers in parenthesis are the number of TA samples assayed per time period. *p < 0.05 (ANOVA repeat 
measures).Page 5 of 11
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ent at 28 days and at 36 weeks PCA. When infants with PH
were excluded from analysis, maximum PDGF-BB con-
centrations remained significantly higher in infants who
were oxygen dependent at 28 days (2900 ± 1391 pg/µg vs.
825 ± 251 pg/µg; p = 0.033). A similar non significant
trend was observed for oxygen dependency at 36 weeks
PCA (3935 ± 2403 pg/µg vs. 1076 ± 253 pg/µg; p = 0.090).
There was no correlation between maximum PDGF-BB
concentrations and Uu isolation in this cohort of infants
(Figure 5B), nor did isolation of Uu from the airways
increase risk for oxygen dependency at either 28 days or
36 weeks PCA. Removal of infants with PH from the anal-
ysis did not alter this finding (data not shown).
Postnatal steroids had an inconsistent effect on those
infants in whom pre and post treatment PDGF-BB con-
centrations were available (17 infants). Seven infants had
a decline in PDGF concentrations 48–72 hours after start-
ing steroids, 5 infants had increased PDGF-BB concentra-
tions and 5 infants had undetectable concentrations at
both sampling times.
Discussion
This study demonstrates that PDGF-BB concentrations
increase during the early stages of RDS in the newborn
and may therefore play a role in ALI in this setting. The
timing of maximal TA PDGF-BB concentrations was simi-
lar to that observed for other inflammatory mediators
Tracheal aspirate concentrations of PDGF-BB normalized to secretory component (sc) during the first 14 days of life in infants who were oxyg n dep dent at 28 postnatal days (black bars) and those wh  were not (white bars)Figur  2
Tracheal aspirate concentrations of PDGF-BB normalized to secretory component (sc) during the first 14 days of life in infants 
who were oxygen dependent at 28 postnatal days (black bars) and those who were not (white bars). Data represent mean ± 
SEM. Numbers in parenthesis are the number of TA samples assayed per time period.Page 6 of 11
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ant protein-1 (MCP-1) in earlier studies [23].
Interstitial and interalveolar fibrosis is a component of
CLD in the newborn. PDGF-BB acts as a potent chemotac-
tic and a "competence" growth factor as well as a mitogen
for fibroblasts and smooth muscle cells [12]. A role of
PDGF-BB in the pathogenesis of lung fibrosis has been
suggested in other fibrotic lung conditions. Conditions
such as idiopathetic pulmonary fibrosis, bronchiolitis
obliterans, and coal-workers pneumoconiosis are associ-
ated with overexpression of PDGF [12-21].
The role of PDGF and other fibroblast growth factors in
RDS and its evolution to CLD has not been extensively
studied in preterm newborn. Currie et al demonstrated
increased fibroblast mitogenic activity in bronchoalveolar
lavage fluid (BALF) in infants with RDS and those who
developed CLD compared with control infants [29]. How-
ever, there was no difference in mitogenic activity between
RDS and CLD infants. In that study, the fibroproliferative
activity of BALF was not blocked by anti-PDGF-BB anti-
body leading the authors to conclude that PDGF-BB did
not significantly contribute to the mitogenic activity.
However, PDGF-BB concentrations were not directly
measured in that study. More recently, Dik et al measured
both PDGF-BB concentrations and fibroblast prolifera-
tion in BALF obtained from 15 infants before and after
systemic dexamethasone [30]. BALF PDGF-BB
concentrations were measurable prior to dexamethasone
Tracheal aspirate concentrations of PDGF-BB normalized to secretory component (sc) during the first 14 days of life in infants who were oxyg n dep dent at 36 weeks PCA (black bars) and th se who were not (white bars)Figur  3
Tracheal aspirate concentrations of PDGF-BB normalized to secretory component (sc) during the first 14 days of life in infants 
who were oxygen dependent at 36 weeks PCA (black bars) and those who were not (white bars). Data represent mean ± SEM. 
Numbers in parenthesis are the number of TA samples assayed per time period.Page 7 of 11
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Maximal TA concentrations PDGF-BB normalized to secretory component (sc) comparing A) infants who were oxygen 
dependent at 36 weeks PCA vs those who were not and B) infants who died or were oxygen dependent at 36 weeks PCA vs 
survivors weaned from oxygen at 36 weeks PCA. Data represent mean ± SEM. *p < 0.05Page 8 of 11
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inhibited by a specific inhibitor of the PDGF receptor
tyrosine kinase. The present study expands and enhances
these observations by providing longitudinal data of TA
PDGF-BB concentrations and correlation with the devel-
opment of CLD. PDGF-BB concentrations from TA fluid
in infants who develop CLD were elevated when com-
pared to those infants who recovered from their initial
lung injury. These results are consistent with a role for
PDGF-BB in the pathogenesis of CLD in the premature
newborn.
The fibrotic process may be activated soon after birth since
the peak concentrations we observed occurred in the first
week of life. This is consistent with other studies that dem-
onstrated elevated concentrations of another pro-fibrotic
factor, transforming growth factor β1 during the first week
of life [3].
We did not observe an effect of dexamethasone on PDGF-
BB concentrations. This lack of inhibition by postnatal
steroid administration on PDGF-BB concentrations was
also observed in Dik et al [30]. In Dik's study, dexameth-
asone increased both PDGF-BB and fibroblast prolifera-
tive properties of BALF.
The early increase in PDGF-BB concentrations may imply
a perinatal insult that influenced the development of
inflammation and fibrosis. We have demonstrated that
airway colonization or infection with Ureaplasma urealyti-
cum is associated with increased concentrations of IL-8
and MCP-1 and may be a contributing factor to the devel-
opment of CLD [23]. However, in this study Uu isolation
was not higher in infants who develop CLD. Comparison
of maximum PDGF-BB concentrations and Uu isolation
revealed no differences.
Pulmonary hemorrhage was associated with an increased
risk of CLD and was associated with increased TA
concentrations of PDGF-BB. This is similar to our earlier
report of increased MCP-1 and IL-8 concentrations in
infants with PH [22]. Hemorrhage into the lung, which
may not be clinically apparent, may be an important
source of PDGF-BB. Platelets are a rich source of PDGF,
particularly PDGF-AB and may account for some of the
PDGF-BB measured in our study [31]. However, PDGF-BB
concentrations were still greater in CLD infants after
infants with clinically significant PH were excluded from
analysis suggesting that PH was not the only determinant
of TA PDGF-BB concentration. Other sources, such as res-
piratory epithelial cells and alveolar macrophages may
also contribute to the PDGF-BB measured [14,32].
All studies of this nature suffer from limitations inherent
in their design. Tracheal aspirate growth factor concentra-
tions may not reflect what is happening at the alveolus or
interstitium of the lung. Moreover, because in clinical
practice infants are extubated as soon as feasible to limit
potential damage from continuing ventilation, infants
who have less severe lung disease or recover from their
acute lung injury rapidly are not sampled. Similar ethical
considerations preclude the use of control infants. Thus,
there are disproportionately fewer samples and fewer time
points in infants who recover, or do not develop chronic
lung disease which introduces bias into our results limit-
ing the conclusions that may be drawn. However, we
believe our results are consistent with other similar clini-
cal studies and in animal models of lung injury providing
further insight into the mechanisms of chronic lung injury
in the newborn.
In our study we employed a higher centrifugation speed
than other studies. This may cause lysis of the cellular
components (ie macrophages) of the TA. Thus TA PDGF-
BB concentrations may reflect total PDGF-BB and not just
free secreted growth factor.
Conclusions
In conclusion, the fibrotic component of chronic lung dis-
ease in preterm infants may be mediated by growth factors
such as PDGF. This study demonstrated that PDGF-BB
concentrations increase in TAs of infants who undergo
mechanical ventilation for RDS during the first week of
life.
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